Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 1 2Phase 3 1

Status

Unknown 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Gynecologic 2Gastrointestinal 2Breast 2Genitourinary 1Dermatologic 1

Conditions

Neoplasm Metastasis 7Carcinoma, Non-Small-Cell Lung 6Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Skin Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Breast Neoplasms 3Recurrence 2Prostatic Neoplasms 2Ovarian Neoplasms 2Neoplasms 2Mycosis Fungoides 2Multiple Myeloma 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, Follicular 2Lymphoma, B-Cell 2Glioblastoma 2Colorectal Neoplasms 2Advanced Malignancies 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Recurrent Squamous Cell Carcinoma of Head 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Myelodysplastic Syndromes 1

Interventions

Fluorouracil 71pembrolizumab 62Bevacizumab 60Oxaliplatin 59Cetuximab 59Leucovorin 56Irinotecan 55Capecitabine 31Nivolumab 23Gemcitabine 18Folfox protocol 18Cisplatin 18IFL protocol 17Cyclophosphamide 16Carboplatin 15atezolizumab 14Specimen Handling 14Paclitaxel 14Magnetic Resonance Spectroscopy 14Biopsy 14trifluridine tipiracil drug combination 12Pemetrexed 10spartalizumab 9regorafenib 9fludarabine 9Panitumumab 9130-nm albumin-bound paclitaxel 9trametinib 8durvalumab 8dehydroftorafur 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Colorectal Neoplasms × cemiplimab × Clear all
NCT06052852 2025-11-17

Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies

Bolt Biotherapeutics, Inc.

Phase 1 Terminated
17 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT04460456 2022-06-30

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

Silverback Therapeutics

Phase 1 Unknown
58 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡